TD Cowen lowered the firm’s price target on Acadia Healthcare (ACHC) to $66 from $70 and keeps a Buy rating on the shares. The firm lowered forward annual EBITDA estimates for by 4% largely to account for additional denovo startup costs and anticipated incremental costs associated with compliance and ramping of new facilities.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare upgraded to Overweight from Sector Weight at KeyBanc
- Acadia Healthcare upgraded to Buy from Hold at Deutsche Bank
- Cantor Fitzgerald ‘cautious’ on Acadia after survey of inpatient psych referrers
- Acadia down 1% following NY Times expose on ‘fraud and fakery’ at clinics
- Acadia Healthcare falsifies records at methadone clinics, NY Times says